The Brigham & Women's Hospital Inc. was awarded a $633,656 Project Grant by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The grant, titled "Improving IL12 Immunogene Therapy for Glioblastoma Based on Human Clinical Trial Results", aims to explore ways to improve the efficacy of intratumoral administration of an IL12 immunogene therapy for treating glioblastoma, one of the most deadly forms of brain cancer. The research will investigate whether the timing of administering immune checkpoint inhibitors (ICI) in combination with the IL12 immunogene therapy, as well as targeting additional immunosuppressive pathways, can enhance the therapeutic response in preclinical glioblastoma models. The award has an ultimate completion date of July 31, 2029.
Generated 3/4/25, 8:34 AM